SciELO - Scientific Electronic Library Online

 
vol.34 número3Manejo de la intolerancia a estatinas: un desafío cotidiano en la práctica clínicaEvolución en el manejo de las dislipemias: análisis comparativo de las guías ESC 2019 versus ACC/AHA 2018 índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Links relacionados

Compartir


Revista Uruguaya de Cardiología

versión impresa ISSN 0797-0048versión On-line ISSN 1688-0420

Resumen

MIRANDA, Natalia. PCSK9 inhibitors: a new era in the control of cardiovascular risk. Rev.Urug.Cardiol. [online]. 2019, vol.34, n.3, pp.356-380.  Epub 01-Dic-2019. ISSN 0797-0048.  https://doi.org/10.29277/cardio.34.3.26.

Statins are still the fundamental piece for cardiovascular risk management. Used in doses of high intensity achieve reductions in cholesterol associated with low density lipoproteins of 50%-60%.

However, in patients with severe hypercholesterolemia, statins alone or associated with ezetimibe may not be sufficient to achieve cholesterol associated with low density lipoproteins decrease targets. Such is the case of genetic dyslipidemias as familial hypercholesterolemia. Also in patients with total or partial statin intolerance, a modern pharmacological alternative is required to reduce high cardiovascular risk. In this scenario, proprotein convertase subtilisin kexin type 9 inhibitors have become a cornerstone to achieve not only a reduction never seen before of cholesterol associated with low density lipoproteins levels, but also of cardiovascular risk. These drugs are in a privilege position due to the new evidence, being effective and well tolerated, with cost as its main limitation despite its marked decline in recent years.

Palabras clave : PCSK9 inhibitors; Hyperlipoproteinemia Type II; Statin Intolerance; Cardiovascular risk.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )